HLS-based acceleration of the BIKE post-quantum KEM on embedded-class heterogeneous SoCs

An effective transition to post-quantum cryptography mandates its deployment on embedded-class devices, guaranteeing adequate performance while satisfying their strict area constraints. This work accelerates BIKE, a QC-MDPC code-based post-quantum KEM, through HLS on embedded-class heterogeneous SoCs that couple a CPU with FPGA programmable logic. The proposed methodology implements HLS-generated accelerators to compute the most time-consuming operations of BIKE, identified by analyzing the software-only execution. The mix of accelerators instantiated in hardware and operations executed in software, as well as the configurable architectural parameters of the former, are then determined, depending on the resources available on the target SoC, to minimize BIKE’s execution time. Experiments on AMD Zynq-7000 SoCs highlight a speedup of up to 3.34 times compared to the reference software execution and up to 1.98 times over state-of-the-art HW/SW implementations targeting the same chips

An Evaluation of the State-of-the-Art Software and Hardware Implementations of BIKE

NIST is conducting a process for the standardization of post-quantum cryptosystems, i.e., cryptosystems that are resistant to attacks by both traditional and quantum computers and that can thus substitute the traditional public-key cryptography solutions which are expected to be broken by quantum computers in the next decades. This manuscript provides an overview and a comparison of the existing state-of-the-art implementations of the BIKE QC-MDPC code-based post-quantum KEM, a candidate in NIST's PQC standardization process. We consider both software, hardware, and mixed hardware-software implementations and evaluate their performance and, for hardware ones, their resource utilization.Comment: Accepted for presentation at PARMA-DITAM 2023: 14th Workshop on Parallel Programming and Run-Time Management Techniques for Many-core Architectures / 12th Workshop on Design Tools and Architectures for Multicore Embedded Computing Platforms, January 17, 202

SARS-CoV-2 vaccination, Parkinson's disease, and other movement disorders: case series and short literature review

BACKGROUND: Several neurological complications have been reported following SARS-Cov-2 vaccination, without a clear causal relationship ever being verified, including some cases of worsening of Parkinson’s disease (PD) symptoms and new onset of movement disorders in non-parkinsonian patients. METHODS: We describe two new cases of PD patients treated with device-aided therapy who developed worsening of parkinsonian symptoms after receiving the third vaccine dose (booster). We also conducted a short review of the cases reported in literature of PD symptoms worsening and new onset of movement disorders in non-parkinsonian patients after SARS-Cov-2 vaccination. RESULTS: The first patient, a 46-year-old man implanted with bilateral Subthalamic Deep Brain Stimulation, experienced temporary motor and non-motor symptoms worsening after mRNA-1273 booster, improved after stimulation settings modification. The second patient, a 55-year-old man implanted with percutaneous endoscopic transgastric jejunostomy (PEG-J) for levodopa-carbidopa intestinal gel (LCIG) infusion experienced severe temporary worsening of dyskinesia and managed through temporary LCIG dose reduction. Other seven cases of vaccine-related movement disorder are currently reported in literature, four describing PD symptoms worsening and three the onset of new movement disorders in otherwise healthy people. CONCLUSION: Both our patients and the cases described so far completely recovered after few days with parkinsonian therapy modification, symptomatic treatment, or even spontaneously, underlining the transient and benign nature of side effects from vaccine. Patients should be reassured about these complications, manageable through a prompt evaluation by the reference neurologist. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10072-022-06182-w

High-speed Source-Device-Independent Quantum Random Number Generator on a Chip

A wide range of applications require, by hypothesis, to have access to a high-speed, private, and genuine random source. Quantum Random Number Generators (QRNGs) are currently the sole technology capable of producing true randomness. However, the bulkiness of current implementations significantly limits their adoption. In this work, we present a high-performance source-device independent QRNG leveraging a custom made integrated photonic chip. The proposed scheme exploits the properties of a heterodyne receiver to enhance security and integration to promote spatial footprint reduction while simplifying its implementation. This characteristics could represents a significant advancement toward the development of generators better suited to meet the demands of portable and space applications. The system can deliver secure random numbers at a rate greater than 20 Gbps with a reduced spatial and power footprint.Comment: 8 pages, 7 figure

Anxiety, depression and worries in advanced Parkinson Disease during COVID-19 pandemic

Background The psychological impact of the COVID-19 outbreak and lockdown on frail populations with advanced Parkinson disease (APD) and their caregivers may present with peculiar features and require specific interventions. Methods We enrolled here 100 APD patients and 60 caregivers. Seventy-four patients were treated with device-aided therapies (DAT) and 26 with standard medical treatment (SMT). Through a telephonic interview, subjects underwent the Hospital Anxiety and Depression Scale (HADS-A; HADS-D), and an ad hoc questionnaire to explore thoughts and emotions related to the pandemic. Results Depression was observed in 35% of APD patients and anxiety in 39%, with a significant reduction of the latter after the lockdown (p= 0.023). We found a significant correlation between the type of therapy and the HADS-A score (p= 0.004). Patients’ main worries were as follows: a possible higher risk of COVID-19 infection (25%), interruption of non-pharmacological treatments (35%), interruption of outpatient clinics (38%), PD complications related to COVID-19 (47%). Patients treated with DAT manifested worries about device-related issues and risk for caregivers’ infection. The 40% of caregivers showed anxiety, while the 21.7% of them showed depression. Conclusion Our study reveals a higher prevalence of anxiety and the presence of peculiar worries and needs in APD patients during the pandemic alongside psychological sequelae of their caregivers. These findings are important for neurologists and healthcare services to foster strategies for the management of psychological distress in both patients and caregivers

Novel R-roscovitine NO-donor hybrid compounds as potential pro-resolution of inflammation agents

AbstractNeutrophils play a pivotal role in the pathophysiology of multiple human inflammatory diseases. Novel pharmacological strategies which drive neutrophils to undergo programmed cell death (apoptosis) have been shown to facilitate the resolution of inflammation. Both the cyclin-dependent kinase inhibitor (CDKi) R-roscovitine and nitric oxide (NO) have been shown to enhance apoptosis of neutrophils and possess pro-resolution of inflammation properties. In order to search for new multi-target pro-resolution derivatives, here we describe the design, synthesis and investigation of the biological potential of a small series of hybrid compounds obtained by conjugating R-roscovitine with two different NO-donor moieties (compounds 2, 9a, 9c). The synthesized compounds were tested as potential pro-resolution agents, with their ability to promote human neutrophil apoptosis evaluated. Both compound 9a and 9c showed an increased pro-apoptotic activity when compared with either R-roscovitine or structurally related compounds devoid of the ability to release NO (des-NO analogues). Inhibition of either NO-synthase or soluble guanylate cyclase did not affect the induction of apoptosis by the R-roscovitine derivatives, similar to that reported for other classes of NO-donors. In contrast the NO scavenger PTIO prevented the enhanced apoptosis seen with compound 9a over R-roscovitine. These data show that novel compounds such as CDKi–NO-donor hybrids may have additive pro-resolution of inflammation effects

Neurological comorbidity and severity of COVID-19

Objective Neurological symptoms of COVID-19 patients have been recently described. However, no comprehensive data have been reported on pre-existing neurological comorbidities and COVID-19. This study aims at evaluating the prevalence of neurological comorbidities, and their association with COVID-19 severity. Methods We evaluated all consecutive patients admitted to the Emergency Room (ER) of our hospital between the 3rd March and the 14th April 2020, and diagnosed with COVID-19. Data on neurological and non-neurological diseases were extracted, as well as data on demographic characteristics and on severity degree of COVID-19. The prevalence of neurological comorbidities was calculated, and multivariate binary logistic regression analyses were used to estimate the association between neurological diseases and COVID-19 severity. Results We included 344 patients. Neurological comorbidities accounted for 22.4% of cases, with cerebrovascular diseases and cognitive impairment being the most frequent. Neurological comorbidity resulted independently associated with severe COVID-19 (OR 2.305; p = 0.012), as well as male gender (p = 0.001), older age (p = 0.001), neoplastic diseases (p = 0.039), and arterial hypertension (p = 0.045). When neurological comorbidity was associated with non-neurological comorbidities, the OR for severe COVID-19 rose to 7.394 (p = 0.005). Neurological patients, in particular cerebrovascular and cognitively impaired ones, received more respiratory support indication. Conclusion Neurological comorbidities represent a significant determinant of COVID-19 severity, deserving a thorough evaluation since the earliest phases of infection. The vulnerability of patients affected by neurological diseases should suggest a greater attention in targeting this population for proactive viral screening